- Home
- ANAB vs IAUX Comparison
ANAB vs IAUX Comparison
Compare ANAB & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | IAUX |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | IAUX |
|---|---|---|
| Price | $55.14 | $1.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $62.20 | $1.50 |
| AVG Volume (30 Days) | 436.9K | ★ 10.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $135.51 | $85.81 |
| Revenue Next Year | N/A | $97.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.99 | $0.48 |
| 52 Week High | $57.65 | $2.24 |
Technical Indicators
Market Signals| Indicator | ANAB | IAUX |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 57.69 |
| Support Level | $46.85 | $1.84 |
| Resistance Level | $57.65 | $2.24 |
| Average True Range (ATR) | 3.51 | 0.14 |
| MACD | 0.48 | -0.00 |
| Stochastic Oscillator | 81.16 | 52.99 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.